Losartan vs Amlodipine: Cost and Access Head-to-Head

How Do Losartan and Amlodipine Actually Compare on Blood Pressure Lowering?

Both drugs reduce systolic blood pressure meaningfully, but amlodipine tends to produce slightly larger absolute reductions in head-to-head analyses. A 2003 meta-analysis of 354 randomized trials (N = 40,020) published in the Lancet found that calcium channel blockers (the class amlodipine belongs to) reduced systolic BP by approximately 8 to 10 mmHg at standard doses, while angiotensin receptor blockers (the class losartan belongs to) reduced systolic BP by approximately 7 to 9 mmHg at comparable doses [1].

No single placebo-controlled trial has compared losartan directly to amlodipine in the same cohort. The evidence base relies on active-comparator trials and class-level meta-analyses.

LIFE Trial: What Losartan Proved

The Losartan Intervention For Endpoint reduction in hypertension (LIFE) trial enrolled 9,193 patients with hypertension and left ventricular hypertrophy. Over a mean follow-up of 4.8 years, losartan produced a 13% reduction in the composite primary endpoint of cardiovascular death, myocardial infarction, and stroke compared with atenolol (a beta-blocker), despite nearly identical blood-pressure lowering between the two arms [1]. The primary endpoint event rate was 23.8 per 1,000 patient-years with losartan versus 27.9 per 1,000 patient-years with atenolol (P<0.001).

The LIFE investigators concluded: "Losartan prevents more cardiovascular morbidity and death than atenolol for the same degree of blood pressure reduction and is better tolerated." [1]

Critically, LIFE did not compare losartan to amlodipine. Its value lies in establishing losartan's organ-protective effects beyond blood pressure reduction.

ASCOT-BPLA Trial: What Amlodipine Proved

The Anglo-Scandinavian Cardiac Outcomes Trial Blood Pressure Lowering Arm (ASCOT-BPLA) randomized 19,257 hypertensive patients to amlodipine-based therapy (adding perindopril as needed) versus atenolol-based therapy (adding bendroflumethiazide as needed). The amlodipine arm was stopped early at 5.5 years because of a significant 10% relative reduction in all-cause mortality and a 23% reduction in fatal and non-fatal stroke [2].

The ASCOT-BPLA investigators reported: "The amlodipine-based regimen was associated with significant reductions in cardiovascular events, procedures, and diabetes compared with the atenolol-based regimen." [2]

Again, this trial compared amlodipine to atenolol rather than to losartan directly. Both LIFE and ASCOT-BPLA demonstrated their respective drugs outperforming atenolol, which positions both as superior to older beta-blocker strategies but leaves their direct comparison dependent on indirect evidence.

Indirect Comparison: Where the Evidence Points

Indirect comparisons from network meta-analyses consistently place CCBs (amlodipine's class) slightly ahead of ARBs (losartan's class) for stroke prevention, while ARBs hold an advantage for patients with proteinuric CKD or heart failure with reduced ejection fraction. The 2021 AHA/ACC hypertension guideline lists both classes as Tier 1 first-line agents, declining to rank one above the other for uncomplicated hypertension [3].

Cost and Cash-Pay Pricing: Which Is Cheaper?

At most U.S. Pharmacies, losartan and amlodipine are essentially the same price. Both have been off-patent long enough that strong generic competition has pushed monthly costs well below $15, even without insurance.

Retail and Discount Pricing in 2024

| Drug | Dose | GoodRx Low (2024) | Walmart $4 List | Costco Generic Program | |---|---|---|---|---| | Losartan | 50 mg, 30 tablets | ~$5 | Yes ($4) | Yes (~$3) | | Losartan | 100 mg, 30 tablets | ~$8 to 14 | Yes ($4) | Yes (~$5) | | Amlodipine | 5 mg, 30 tablets | ~$4 to 7 | Yes ($4) | Yes (~$3) | | Amlodipine | 10 mg, 30 tablets | ~$7 to 12 | Yes ($4) | Yes (~$4) |

Prices vary by pharmacy and region. Patients using GoodRx, NeedyMeds, or a warehouse pharmacy club can expect to pay under $10 monthly for either drug at any standard dose.

Insurance Coverage and Formulary Tier

Both drugs sit on Tier 1 of nearly every commercial formulary and most Medicare Part D plans, meaning the patient copay is $0, $5 with most insurance. Prior authorization is rarely required for either drug when prescribed for hypertension. Patients switching between the two drugs mid-plan year may encounter a brief formulary confirmation step, but this resolves within 24 to 48 hours in most cases.

Medicaid coverage is near-universal for both drugs in all 50 states, typically at no cost to the patient.

Cost Advantage for Combination Pills

Amlodipine is available as a fixed-dose combination with olmesartan (Azor), valsartan (Exforge), or telmisartan (Twynsta). Losartan is available as a fixed-dose combination with hydrochlorothiazide (Hyzaar). Both combination pills carry generic versions that remain affordable. If a patient needs two antihypertensives, the combination pill may reduce total monthly spend by eliminating a second copay tier.

Side-Effect Profiles: Practical Differences That Drive Drug Choice

The two drugs have distinct adverse-effect patterns. Knowing them in advance reduces the chance of an unnecessary medication switch.

Amlodipine Side Effects

Peripheral edema is the most common complaint with amlodipine, affecting roughly 10% of patients at 5 mg and up to 30% at 10 mg [4]. The edema results from precapillary vasodilation that increases capillary hydrostatic pressure, and it is dose-dependent. Switching to a lower dose or adding an ARB (which counters the hemodynamic mechanism) typically resolves the edema without abandoning the drug.

Other side effects include flushing, headache, and palpitations, each occurring in 1%, 3% of patients. Gingival hyperplasia is rare but documented with dihydropyridine CCBs.

Losartan Side Effects

Losartan is generally well tolerated. Unlike ACE inhibitors, it does not cause the ACE-inhibitor cough because it does not raise bradykinin. Hyperkalemia is the most clinically significant risk, particularly in patients with CKD or those taking potassium-sparing diuretics. Serum potassium should be checked at baseline and again 2 to 4 weeks after initiation in patients with CKD or diabetes [5].

Dizziness on first dose occurs in some patients due to blood-pressure reduction. Losartan at 50 to 100 mg also has a mild uricosuric effect, reducing serum uric acid by approximately 15%, 25%, which may benefit patients with gout [6].

Head-to-Head Tolerability

In LIFE, losartan was associated with fewer drug discontinuations due to adverse effects than atenolol (9.7% vs. 14.9%). In ASCOT-BPLA, the amlodipine-based regimen led to fewer adverse events requiring treatment cessation than the atenolol arm. Neither trial compared the two drugs to each other directly, but the overall discontinuation profiles in large post-marketing registries are similar: roughly 10%, 12% of patients stop either drug within 12 months for any reason.

Which Patients Benefit More From Losartan?

Losartan carries guideline-backed advantages in specific clinical scenarios where its renin-angiotensin system blockade provides organ protection beyond blood-pressure lowering.

Diabetic Kidney Disease

The RENAAL trial (N = 1,513) showed that losartan 100 mg reduced the risk of doubling of serum creatinine by 25% and end-stage renal disease by 28% compared with placebo in patients with type 2 diabetes and nephropathy, independent of blood-pressure differences between groups [5]. The American Diabetes Association (ADA) Standards of Care recommends ARBs or ACE inhibitors as first-line antihypertensive therapy in patients with diabetes and albuminuria [7].

Marfan Syndrome and Aortic Root Dilation

Losartan has been studied for slowing aortic root dilation in Marfan syndrome via TGF-beta pathway inhibition. The COMPARE trial (N = 233) found losartan 100 mg did not statistically outperform beta-blockers on aortic root growth rate, but it remains commonly used off-label given its favorable safety profile in this population [8].

Gout Comorbidity

Because losartan reduces serum uric acid, it is the preferred ARB when a patient with hypertension also has gout or hyperuricemia. The reduction is modest (15%, 25%), not a substitute for urate-lowering therapy, but it avoids the slight uric acid elevation seen with thiazide diuretics and some other agents.

Which Patients Benefit More From Amlodipine?

Amlodipine holds advantages in several clinical contexts, particularly when coronary artery disease or stroke prevention is the primary concern.

Stable Angina

Amlodipine is FDA-approved for chronic stable angina and vasospastic (Prinzmetal) angina. Losartan carries no angina indication. The CAMELOT trial (N = 1,991) compared amlodipine to enalapril and placebo in patients with coronary artery disease and normal blood pressure, finding amlodipine reduced cardiovascular events by 31% versus placebo (P<0.001) [9]. Patients with both hypertension and angina get a two-for-one benefit from amlodipine.

Isolated Systolic Hypertension in Older Adults

Calcium channel blockers have historically performed well in trials enrolling older adults with isolated systolic hypertension. The Syst-Eur trial, which used nitrendipine (a CCB related to amlodipine), found a 42% reduction in stroke incidence compared with placebo in patients over age 60 with isolated systolic hypertension. Amlodipine is the standard CCB used in current practice for this indication.

No ACE-Inhibitor Cough and No ARB Limitation

Patients who have already failed an ACE inhibitor due to cough may be offered either losartan (same drug class benefit, no cough) or amlodipine (different mechanism entirely). If the patient also has hyperkalemia or a potassium above 5.0 mEq/L, amlodipine avoids the additional potassium burden of renin-angiotensin blockade.

Drug Interactions and Contraindications

Losartan Drug Interactions

Losartan is metabolized by CYP2C9 to its active metabolite, E-3174. Drugs that inhibit CYP2C9 (such as fluconazole) can raise losartan levels, while rifampin can lower them. Non-steroidal anti-inflammatory drugs (NSAIDs) blunt the antihypertensive effect and increase the risk of acute kidney injury when combined with ARBs, particularly in patients with CKD or volume depletion.

Combining losartan with an ACE inhibitor (dual RAAS blockade) is not recommended. The ONTARGET trial (N = 25,620) found that combining telmisartan plus ramipril offered no additional cardiovascular benefit over monotherapy while increasing hypotension, syncope, renal impairment, and hyperkalemia [10].

Amlodipine Drug Interactions

Amlodipine is metabolized by CYP3A4. Strong CYP3A4 inhibitors, including clarithromycin, ketoconazole, and ritonavir, can significantly raise amlodipine plasma concentrations and increase the risk of hypotension and edema. Simvastatin dose should not exceed 20 mg/day when co-administered with amlodipine, per FDA labeling, due to increased risk of myopathy [11].

Shared Contraindications

Both drugs are contraindicated in pregnancy. Losartan and other ARBs carry FDA Pregnancy Category D labeling (now described under the PLLR system as causing fetal harm including oligohydramnios, renal tubular dysplasia, and neonatal renal failure). Amlodipine is generally avoided in pregnancy due to limited safety data, though its risk profile differs mechanistically.

Switching Between Losartan and Amlodipine

Switching is medically straightforward but should be guided by a clinician. The two drugs work by completely different mechanisms and have no cross-reactivity or withdrawal risk.

A practical framework for switching used at HealthRX:

1. Confirm the reason for switching. Side effects (edema, hyperkalemia), cost, formulary change, or new comorbidity each point to different replacement options.
2. Stop one, start the other on the same day. No dose-tapering period is required for either drug. Blood pressure may fluctuate for 2 to 5 days during the transition.
3. Recheck BP at 2 to 4 weeks. Amlodipine reaches steady-state in 7 to 8 days due to its long half-life (35 to 50 hours). Losartan reaches steady-state within 3 to 5 days.
4. Check labs if switching to losartan. Obtain a basic metabolic panel at the 2 to 4 week mark to check for hyperkalemia and any renal function change, especially in patients with CKD or diabetes.
5. Titrate if target BP is not met. Both drugs allow dose escalation: losartan from 25 mg to 50 mg to 100 mg daily; amlodipine from 2.5 mg to 5 mg to 10 mg daily.

Combination Therapy: When One Drug Is Not Enough

Roughly 50%, 70% of patients with hypertension require two or more agents to reach a systolic target below 130 mmHg, per the 2017 ACC/AHA guideline threshold [3]. Losartan and amlodipine are frequently combined with each other.

The ACCOMPLISH trial (N = 11,506) compared benazepril (an ACE inhibitor, same class mechanism as losartan) plus amlodipine versus benazepril plus hydrochlorothiazide. The ACE inhibitor plus amlodipine arm reduced cardiovascular events by 19.6% compared with the ACE inhibitor plus diuretic arm (P<0.001) [12]. While losartan is an ARB rather than an ACE inhibitor, the findings support the combination of RAAS blockade with a CCB as a preferred two-drug regimen.

Adding amlodipine to losartan (or vice versa) is therefore both guideline-supported and pharmacologically rational: the two drugs act on independent pathways, their side effects do not overlap in clinically meaningful ways, and generic versions of both remain inexpensive.

Telehealth Access and Prescription Patterns

Both losartan and amlodipine are available via telehealth platforms in all 50 states for patients with an established diagnosis of hypertension. Neither drug requires a controlled-substance waiver, DEA registration, or state-level prescribing restriction.

Telehealth prescribers typically require:

• A blood pressure reading (home cuff, pharmacy kiosk, or prior clinic record)
• A list of current medications to check for interactions
• Basic metabolic panel within the prior 12 months for losartan, to assess renal function and potassium

Amlodipine can often be initiated without lab prerequisites in otherwise healthy adults. Losartan initiation in patients with CKD stage 3 or above benefits from a recent creatinine and potassium result before the first prescription is issued.